BridgeBio Oncology insider covers taxes with shares

BridgeBio Oncology Therapeutics, Inc. former officer Uneek Mehra reported a small share disposition tied to taxes, not an open-market trade.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. former officer Uneek Mehra reported a small share disposition tied to taxes, not an open-market trade. On the vesting of restricted stock units, the company withheld 524 shares of Common Stock at $9.03 per share to cover tax withholding obligations. After this tax-withholding transaction, Mehra directly holds 22,806 shares of BridgeBio Oncology common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 524 shares

Exercise Price or Tax Liability 1 txn

Insider Mehra Uneek

Role Insider

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	524	$9.03	$5K

Holdings After Transaction: Common Stock — 22,806 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Key Figures

Shares withheld for taxes: 524 shares Withholding reference price: $9.03 per share Shares held after transaction: 22,806 shares +2 more

5 metrics

Shares withheld for taxes 524 shares Withheld to satisfy tax obligations on RSU vesting

Withholding reference price $9.03 per share Value used for 524-share tax-withholding disposition

Shares held after transaction 22,806 shares Directly held BridgeBio Oncology common stock post-Form 4

Disposition type 1 tax-withholding transaction Code F, payment of tax liability by delivering securities

Tax-withholding shares total 524 shares Total shares classified as tax withholding in transaction summary

Key Terms

restricted stock units, tax withholding obligations, Common Stock, tax-withholding disposition

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

Common Stock financial

"shares of the Issuer's Common Stock withheld by the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did former officer Uneek Mehra report in the BridgeBio Oncology (BBOT) Form 4?

Uneek Mehra reported a disposition of BridgeBio Oncology common stock tied to tax withholding, not a market trade. The issuer withheld 524 shares upon RSU vesting to satisfy tax obligations, leaving Mehra with 22,806 directly held shares after the transaction.

Was the BridgeBio Oncology (BBOT) Form 4 transaction an open-market sale?

No, the transaction was classified as a tax-withholding disposition, not an open-market sale. Shares were withheld by BridgeBio Oncology to cover Uneek Mehra’s tax obligations when restricted stock units vested, according to the filing’s F-code and accompanying explanatory footnote.

How many BridgeBio Oncology (BBOT) shares were withheld for taxes in this filing?

The filing shows 524 shares of BridgeBio Oncology common stock were withheld. These shares satisfied Uneek Mehra’s tax withholding obligations related to vesting restricted stock units, rather than being sold in the open market for investment or trading purposes.

What is Uneek Mehra’s BridgeBio Oncology (BBOT) shareholding after this Form 4 event?

After the tax-withholding disposition, Uneek Mehra directly holds 22,806 shares of BridgeBio Oncology common stock. This figure reflects the remaining position following the 524 shares withheld by the issuer in connection with restricted stock unit vesting and related tax obligations.

What does the F transaction code mean in the BridgeBio Oncology (BBOT) Form 4?

The F transaction code indicates shares were disposed of to pay taxes or exercise costs. Here, it reflects BridgeBio Oncology withholding shares from Uneek Mehra to meet tax obligations on restricted stock unit vesting, rather than a discretionary buy or sell decision in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 07:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehra Uneek

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		F		524(1)	D	$9.03	22,806	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Aaron Chan, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)